DK3630725T3 - Krystallinsk form af n-butyldeoxygalactonojirimycin - Google Patents
Krystallinsk form af n-butyldeoxygalactonojirimycinInfo
- Publication number
- DK3630725T3 DK3630725T3 DK18728624.0T DK18728624T DK3630725T3 DK 3630725 T3 DK3630725 T3 DK 3630725T3 DK 18728624 T DK18728624 T DK 18728624T DK 3630725 T3 DK3630725 T3 DK 3630725T3
- Authority
- DK
- Denmark
- Prior art keywords
- butyldeoxygalactonojirimycin
- crystalline form
- crystalline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017063287 | 2017-06-01 | ||
| PCT/EP2018/064365 WO2018220131A1 (en) | 2017-06-01 | 2018-05-31 | Crystalline form of n-butyldeoxygalactonojirimycin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3630725T3 true DK3630725T3 (da) | 2026-02-09 |
Family
ID=62492649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18728624.0T DK3630725T3 (da) | 2017-06-01 | 2018-05-31 | Krystallinsk form af n-butyldeoxygalactonojirimycin |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US11306058B2 (da) |
| EP (1) | EP3630725B1 (da) |
| JP (2) | JP6937850B2 (da) |
| KR (1) | KR102612650B1 (da) |
| CN (1) | CN110799497A (da) |
| AU (1) | AU2018278247B2 (da) |
| CA (1) | CA3065147A1 (da) |
| CL (1) | CL2019003478A1 (da) |
| DK (1) | DK3630725T3 (da) |
| EA (1) | EA201992807A1 (da) |
| ES (1) | ES3059191T3 (da) |
| FI (1) | FI3630725T3 (da) |
| HR (1) | HRP20251697T1 (da) |
| IL (1) | IL270961B2 (da) |
| LT (1) | LT3630725T (da) |
| MA (1) | MA48944B1 (da) |
| MX (1) | MX2019014427A (da) |
| MY (1) | MY201196A (da) |
| NZ (1) | NZ760100A (da) |
| PH (1) | PH12019502635A1 (da) |
| PL (1) | PL3630725T3 (da) |
| PT (1) | PT3630725T (da) |
| RS (1) | RS67675B1 (da) |
| SI (1) | SI3630725T1 (da) |
| TW (1) | TWI770184B (da) |
| UA (1) | UA125938C2 (da) |
| WO (1) | WO2018220131A1 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20251697T1 (hr) * | 2017-06-01 | 2026-02-27 | Idorsia Pharmaceuticals Ltd | Kristalni oblik n-butildeoksigalaktonojirimicina |
| ES3062389T3 (en) | 2019-09-25 | 2026-04-10 | Assia Chem Ind Ltd | Solid state forms of lucerastat salts and process for preparation thereof |
| WO2025017212A1 (en) | 2023-07-20 | 2025-01-23 | Katholieke Universiteit Leuven | Udp-glucose ceramide glucosyltransferase synthase (ugcg) inhibitors in the treatment of cancer |
| TR2024011149A1 (tr) * | 2024-08-23 | 2026-03-23 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Mi̇galastat i̇çeren kapsül formülasyonlari |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0536402A4 (en) * | 1990-06-29 | 1993-05-12 | Nippon Shinyaku Company, Limited | Piperidine derivative |
| US6291657B1 (en) * | 1993-05-13 | 2001-09-18 | Monsanto Company | Deoxygalactonojirimycin derivatives |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| GB0100889D0 (en) | 2001-01-12 | 2001-02-21 | Oxford Glycosciences Uk Ltd | Compounds |
| GB0229476D0 (en) * | 2002-12-17 | 2003-01-22 | Oxford Glycosciences Uk Ltd | Novel process |
| FR2861991B1 (fr) * | 2003-11-07 | 2008-01-18 | Centre Nat Rech Scient | Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose |
| WO2006037069A1 (en) | 2004-09-28 | 2006-04-06 | Allergan, Inc. | Compositions comprising nb-dnj, ne-dnj or d-glucaro-delta-lactam and their uses for the treatment of pain and other neurological conditions |
| EP3782655A1 (en) | 2005-05-17 | 2021-02-24 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
| CN101267779A (zh) | 2005-07-27 | 2008-09-17 | 福罗里达大学研究基金会有限公司 | 使用热休克治疗眼睛疾病 |
| DE602007008870D1 (de) | 2006-04-24 | 2010-10-14 | Amc Amsterdam | Verbessertes verfahren zur behandlung von cystischer fibrose |
| GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
| ITMI20122090A1 (it) | 2012-12-06 | 2014-06-07 | Dipharma Francis Srl | Sintesi di un inibitore delle glicosiltransferasi |
| HRP20251697T1 (hr) * | 2017-06-01 | 2026-02-27 | Idorsia Pharmaceuticals Ltd | Kristalni oblik n-butildeoksigalaktonojirimicina |
-
2018
- 2018-05-31 HR HRP20251697TT patent/HRP20251697T1/hr unknown
- 2018-05-31 IL IL270961A patent/IL270961B2/en unknown
- 2018-05-31 ES ES18728624T patent/ES3059191T3/es active Active
- 2018-05-31 SI SI201831279T patent/SI3630725T1/sl unknown
- 2018-05-31 FI FIEP18728624.0T patent/FI3630725T3/fi active
- 2018-05-31 RS RS20260062A patent/RS67675B1/sr unknown
- 2018-05-31 DK DK18728624.0T patent/DK3630725T3/da active
- 2018-05-31 KR KR1020197038894A patent/KR102612650B1/ko active Active
- 2018-05-31 CA CA3065147A patent/CA3065147A1/en active Pending
- 2018-05-31 NZ NZ760100A patent/NZ760100A/en unknown
- 2018-05-31 TW TW107118696A patent/TWI770184B/zh active
- 2018-05-31 PT PT187286240T patent/PT3630725T/pt unknown
- 2018-05-31 MA MA48944A patent/MA48944B1/fr unknown
- 2018-05-31 WO PCT/EP2018/064365 patent/WO2018220131A1/en not_active Ceased
- 2018-05-31 MY MYPI2019007035A patent/MY201196A/en unknown
- 2018-05-31 JP JP2019566190A patent/JP6937850B2/ja active Active
- 2018-05-31 LT LTEPPCT/EP2018/064365T patent/LT3630725T/lt unknown
- 2018-05-31 CN CN201880035373.9A patent/CN110799497A/zh active Pending
- 2018-05-31 PL PL18728624.0T patent/PL3630725T3/pl unknown
- 2018-05-31 US US16/618,036 patent/US11306058B2/en active Active
- 2018-05-31 EP EP18728624.0A patent/EP3630725B1/en active Active
- 2018-05-31 MX MX2019014427A patent/MX2019014427A/es unknown
- 2018-05-31 AU AU2018278247A patent/AU2018278247B2/en active Active
- 2018-05-31 EA EA201992807A patent/EA201992807A1/ru unknown
- 2018-05-31 UA UAA201912130A patent/UA125938C2/uk unknown
-
2019
- 2019-11-22 PH PH12019502635A patent/PH12019502635A1/en unknown
- 2019-11-28 CL CL2019003478A patent/CL2019003478A1/es unknown
-
2021
- 2021-08-31 JP JP2021140904A patent/JP7373529B2/ja active Active
- 2021-09-20 US US17/479,341 patent/US11713297B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3810581T3 (da) | Krystalmodifikationer af odevixibat | |
| DK3978483T3 (da) | Krystallinsk toluensolvat af (s)-afoxolaner | |
| IL268852A (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3371171T3 (da) | Inhibitorer af RET | |
| DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3377059T3 (da) | Hæmmere af cxcr2 | |
| DK3509581T3 (da) | Formuleringer af (r)-2-amino-3-phenylpropylcarbamat | |
| DK3554240T3 (da) | Kombinationer af aktive forbindelser | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3668851T3 (da) | Fremgangsmåde til fremstilling af thiocarbonater | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| DK3300500T3 (da) | Triazolagonister af apj-receptoren | |
| HUE064559T2 (hu) | MAGL inhibitor kristályos formája | |
| DK3180331T3 (da) | Polymorfer af selinexor | |
| DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| DK3798222T3 (da) | Krystallinsk form af den frie base af lorlatinib | |
| DK3457851T3 (da) | Derivater af sobetirom | |
| DK3649781T3 (da) | Forbedring af tvungen grænseopdeling | |
| DK3551625T3 (da) | Heterocykliske inhibitorer af mct4 | |
| DK3220891T3 (da) | Sublingual formulering af riluzol | |
| IL269792B (en) | Crystalline forms of (s)-afoxolaner | |
| DK3474822T3 (da) | Formuleringer af brincidofovir | |
| DK3370949T3 (da) | Sammensætning af tætningsmiddel | |
| DK3943070T3 (da) | Langtidsvirkende formuleringer af bedaquilin |